Pioglitazone Did Not Affect PPAR-Γ, STAT5, HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

被引：4
|
作者：
Lopes, Ana Beatriz Pascoal [1 ]
Miranda, Eliana C. [1 ]
Povoa, Valquiria Mariane Oliveira [1 ]
Vergilio, Bruna Rocha [1 ]
Furlin, Graziele Cristina Pavan [1 ]
Delamain, Marcia Torresan [1 ]
Duarte, Gislaine Borba [1 ]
Souza, Carmino Antonio [1 ]
De Paula, Erich V. [2 ]
Pagnano, Katia B. [1 ]
机构：
[1] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Campinas, SP, Brazil
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128265
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1637
引用
收藏
页数：3
相关论文
共 14 条
  • [1] Kinetics of CITED2 Gene Expression in Chronic Myeloid Leukemia Patients
    Atef, Basma
    El-Ashwah, Shaimaa
    Saleh, Layla M.
    Gawish, Hanan
    Mabed, Mohamed
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S292 - S292
  • [2] Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)
    Scherr, M
    Chaturvedi, A
    Battmer, K
    Dallmann, I
    Schultheis, B
    Ganser, A
    Eder, M
    BLOOD, 2006, 107 (08) : 3279 - 3287
  • [3] Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response
    Pagnano, Katia B. B.
    Lopes, Ana Beatriz P.
    Miranda, Eliana C.
    Delamain, Marcia T.
    Duarte, Gislaine O.
    Rodrigues, Bruna R. V.
    Povoa, Valquiria M. O.
    Furlin, Graziele C. P.
    Vianna, Jessica C.
    da Silva, Matheus A. S.
    De Souza, Carmino A.
    De Paula, Erich, V
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : E321 - E323
  • [4] CONCURRENT USE OF PROTON PUMP INHIBITORS (PPI) OR H2-BLOCKERS DID NOT ADVERSELY AFFECT NILOTINIB RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
    Yin, O. Q.
    Giles, F. J.
    Baccarani, M.
    le Coutre, P.
    Chia, Y. L.
    Gallagher, N.
    Saglio, G.
    Hughes, T. P.
    Hochhaus, A.
    Kantarjian, H. M.
    Larson, R. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S78 - S79
  • [5] B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line
    Da Silva, Matheus Sebastian
    Miranda, Eliana C.
    Delamain, Marcia Torresan
    Duarte, Gislaine Oliveira
    Vergilio, Bruna R.
    Pascoal Lopes, Ana Beatriz
    Vianna, Jessica C. N.
    De Souza, Carmino Antonio
    De Paula, Erich Vinicius
    Pagnano, Katia B.
    BLOOD, 2018, 132
  • [6] ASSOCIATION OF BCL2L11 (BIM) DELETION POLYMORPHISM WITH MOLECULAR RELAPSE AFTER TYROSINE KINASE INHIBITOR CESSATION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
    Katagiri, S.
    Tauchi, T.
    Tanaka, Y.
    Ando, K.
    Okabe, S.
    Gotoh, M.
    Ito, Y.
    Umezu, T.
    Tadokoro, K.
    Ohyashiki, J. H.
    Ohyashiki, K.
    HAEMATOLOGICA, 2017, 102 : 442 - 442
  • [7] Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data
    Pungolino, Ester
    D'adda, Mariella
    Trojani, Alessandra
    Perego, Alessandra
    Elena, Chiara
    Iurlo, Alessandra
    Malato, Simona
    Turrini, Mauro
    De Canal, Gabriella
    Borin, Lorenza
    Lodola, Milena
    Caramella, Marianna
    Artale, Salvatore
    Spina, Francesco
    Latargia, Maria Luisa
    Anghilieri, Michela
    Spedini, Pierangelo
    Carraro, Mariacristina
    Di Camillo, Barbara
    Gramegna, Doriana
    Pioltelli, Maria Luisa
    Rossi, Giuseppe
    Morra, Enrica
    Cairoli, Roberto
    BLOOD, 2018, 132
  • [8] Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N-Road study
    Nishiwaki, Kaichi
    Sugimoto, Kei-ji
    Tamaki, Shigehisa
    Hisatake, Junichi
    Yokoyama, Hisayuki
    Igarashi, Tadahiko
    Shinagawa, Atsushi
    Sugawara, Takeaki
    Hara, Satoru
    Fujikawa, Kazuhisa
    Shimizu, Seiichi
    Yujiri, Toshiaki
    Tojo, Arinobu
    Wakita, Hisashi
    CANCER MEDICINE, 2020, 9 (11): : 3742 - 3751
  • [9] A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1
    Heibl, Sonja
    Buxhofer-Ausch, Veronika
    Schmidt, Stefan
    Webersinke, Gerald
    Lion, Thomas
    Piringer, Gudrun
    Kuehr, Thomas
    Wolf, Dominik
    Melchardt, Thomas
    Greil, Richard
    Thaler, Josef
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (05) : 792 - 798
  • [10] The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial
    Esposito, Nicola
    Quarantelli, Fabrizio
    Luciano, Luigia
    Izzo, Barbara
    Peluso, Anna Lucia
    Picardi, Marco
    Branford, Susan
    White, D. L.
    Hughes, Timothy
    Radich, Jerald
    Soverini, Simona
    Iacobucci, Ilaria
    Saglio, Giuseppe
    Kalebic, Thea
    Thomquist, Mark
    Martinelli, Giovanni
    Pane, Fabrizio
    BLOOD, 2008, 112 (11) : 404 - 404
12